首页> 外文OA文献 >Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

【2h】

Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

机译：醛固酮受体拮抗作用在慢性肾脏病（BARACK D）试验中的益处-一项多中心，前瞻性，随机，开放，盲点终点研究，为期3个月，研究对象为2,616名3b期慢性肾脏病初级保健患者，以比较螺内酯25 mg每日一次除常规治疗对死亡率和心血管结局的疗效与仅常规治疗相比：一项随机对照试验的研究方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nathan R Hill; Daniel Lasserson; Ben Thompson; Rafael Perera-Salazar; Jane Wolstenholme; Peter Bower; Thomas Blakeman; David Fitzmaurice; Paul Little; Gene Feder; Nadeem Qureshi; Maarten Taal; Jonathan Townend; Charles Ferro; Richard McManus; FD Hobbs;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25?mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial [J] . Nathan R Hill, Daniel Lasserson, Ben Thompson, Trials . 2014,第1期

机译：醛固酮受体拮抗作用在慢性肾脏病（BARACK D）试验中的益处-一项多中心，前瞻性，随机，开放，盲点终点研究，为期3个月，研究对象为2,616名3b期慢性肾脏病初级保健患者，以比较螺内酯25毫克/天的常规治疗对死亡率和心血管疾病的疗效，与常规治疗相比，每天一次：随机对照试验的研究方案
2. United Kingdom Frozen Shoulder Trial (UK FROST), multi-centre, randomised, 12 month, parallel group, superiority study to compare the clinical and cost-effectiveness of Early Structured Physiotherapy versus manipulation under anaesthesia versus arthroscopic capsular release for patients referred to secondary care with a primary frozen shoulder: study protocol for a randomised controlled trial [J] . Stephen Brealey, Alison L. Armstrong, Andrew Brooksbank, Trials . 2017,第1期

机译：英国冷冻肩部试验（UK FROST），多中心，随机，12个月，平行组的优势研究，比较了二级医疗机构中早期结构化物理疗法与麻醉下手法与关节镜下囊膜释放的临床和成本效益原发性肩周炎：随机对照试验的研究方案
3. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III–IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial [J] . Jing Gan, Yansheng Wu, Xuezhong Gong, Trials . 2019,第1期

机译：Yinang配方与安慰剂颗粒作为慢性肾病患者治疗III-IV患者术患者，常染色体显性多囊肾脏疾病：双盲安慰剂可随机临床试验的研究方案
4. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre prospective randomised open blinded end-point 36-month study of 2616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial [O] . Nathan R Hill, Daniel Lasserson, Ben Thompson, 2014

机译：醛固酮受体拮抗作用在慢性肾脏病（BARACK D）试验中的益处-一项多中心前瞻性随机开放盲点终点研究为期3个月研究对象为2616名3b期慢性肾脏病初级保健患者以比较螺内酯25 mg每日一次除常规治疗对死亡率和心血管结局的疗效与仅常规治疗相比：一项随机对照试验的研究方案
5. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial [O] . Hill, NR, Lasserson, D, Thompson, B, 2014

机译：醛固酮受体拮抗作用在慢性肾脏病（BARACK D）试验中的益处–一项多中心，前瞻性，随机，开放，盲点终点研究，为期3个月，研究对象为2,616名3b期慢性肾脏病初级保健患者，以比较螺内酯25 mg除常规治疗对死亡率和心血管结局的每日疗效与单独常规治疗相比，每天一次：随机对照试验的研究方案

著录项

相似文献

相关主题

期刊订阅